Stefano Fanti

Research interests

Publications

• Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

  European Urology · 2024 · https://doi.org/10.1016/j.eururo.2024.09.017

• Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

  European Journal of Cancer · 2023 · https://doi.org/10.1016/j.ejca.2023.02.018

• Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

  European Journal of Nuclear Medicine and Molecular Imaging · 2023 · https://doi.org/10.1007/s00259-023-06255-8

• Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

  European Urology · 2020 · https://doi.org/10.1016/j.eururo.2020.01.012

• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

  European Urology · 2020 · https://doi.org/10.1016/j.eururo.2020.09.042

• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer

  European Urology · 2020 · https://doi.org/10.1016/j.eururo.2020.09.046

• Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review

  European Urology · 2020 · https://doi.org/10.1016/j.eururo.2020.01.033

• Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations

  European Urology Focus · 2019 · https://doi.org/10.1016/j.euf.2019.06.004

• EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)

  European Journal of Nuclear Medicine and Molecular Imaging · 2019 · https://doi.org/10.1007/s00259-019-04485-3

• EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†

  European Urology · 2019 · https://doi.org/10.1016/j.eururo.2019.09.035

• EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz296

• EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study)

  European Urology · 2019 · https://doi.org/10.1016/j.eururo.2019.09.020

• Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review

  European Urology · 2018 · https://doi.org/10.1016/j.eururo.2018.10.011

• Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F–DOPA

  European Journal of Nuclear Medicine and Molecular Imaging · 2017 · https://doi.org/10.1007/s00259-017-3728-y

• 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0

  European Journal of Nuclear Medicine and Molecular Imaging · 2017 · https://doi.org/10.1007/s00259-017-3670-z

• Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

  European Urology · 2017 · https://doi.org/10.1016/j.eururo.2017.06.002

• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging

  Neuroendocrinology · 2017 · https://doi.org/10.1159/000471879

• 18F-FACBC (anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) versus 11C-choline PET/CT in prostate cancer relapse: results of a prospective trial

  European Journal of Nuclear Medicine and Molecular Imaging · 2016 · https://doi.org/10.1007/s00259-016-3329-1

• Prospective Comparison of 18 F-Fluoromethylcholine Versus 68 Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy

  Journal of Nuclear Medicine · 2015 · https://doi.org/10.2967/jnumed.115.160382

• Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?

  European Journal of Nuclear Medicine and Molecular Imaging · 2010 · https://doi.org/10.1007/s00259-010-1604-0

• Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE

  European Journal of Nuclear Medicine and Molecular Imaging · 2010 · https://doi.org/10.1007/s00259-010-1512-3

• Influence of Trigger PSA and PSA Kinetics on 11C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy

  Journal of Nuclear Medicine · 2009 · https://doi.org/10.2967/jnumed.108.061507

• 11C-Choline Positron Emission Tomography/Computerized Tomography for Preoperative Lymph-Node Staging in Intermediate-Risk and High-Risk Prostate Cancer: Comparison with Clinical Staging Nomograms

  European Urology · 2008 · https://doi.org/10.1016/j.eururo.2008.04.030

• Prostate Cancer: Sextant Localization with MR Imaging, MR Spectroscopy, and11C-Choline PET/CT

  Radiology · 2007 · https://doi.org/10.1148/radiol.2443061063

• Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis.

  PubMed · 2005

Current projects

No projects listed.